Artiva Biotherapeutics (Nasdaq: ARTV) will host a virtual webcast on November 12, 2025 at 8 a.m. ET to discuss initial safety and translational data for AlloNK® plus anti-CD20 antibodies in autoimmune disease.
Key disclosed items: initial safety data in 32 patients reporting a forable tolerability profile and outpatient feasibility; translational results showing uniform, deep B-cell depletion; a high-sensitivity B-cell assay with 10- to 50-fold greater sensitivity; and characterisation of the unmet need in refractory rheumatoid arthritis. A live Q&A and replay will be ailable via the company website.
Artiva Biotherapeutics (Nasdaq: ARTV) terrà un webcast virtuale il 12 novembre 2025 alle ore 8:00 ET per discutere i dati iniziali di sicurezza e di traduzione per AlloNK® + anticorpi anti-CD20 nelle malattie autoimmuni.
Elementi chie divulgati: dati iniziali di sicurezza in 32 pazienti che riportano un profilo di tollerabilità forevole e fattibilità ambulatoriale; risultati tradizionali che mostrano una deplezione dei linfociti B uniforme e profonda; un test B-cell ad alta sensibilità con 10-50 volte superiore sensibilità; e la caratterizzazione del bisogno non soddisfatto nell’artrite reumatoide refrattaria. Un Q&A in diretta e la riproduzione saranno disponibili sul sito dell’azienda.
Artiva Biotherapeutics (Nasdaq: ARTV) celebrará una webcast virtual el 12 de noviembre de 2025 a las 8:00 a.m. ET para discutir datos iniciales de seguridad y translación para AlloNK® más anticuerpos anti-CD20 en enfermedades autoinmunes.
Elementos cle divulgados: datos iniciales de seguridad en 32 pacientes que informan un perfil de tolerabilidad forable y viabilidad ambulatoria; resultados traslacionales que muestran una deleción de células B uniforme y profunda; un ensayo de células B de alta sensibilidad con 10- a 50-veces mayor sensibilidad; y la caracterización de las necesidades no satisfechas en la artritis reumatoide refractaria. Habrá una sesión de preguntas y respuestas en vivo y una reproducción disponible a trés del sitio web de la empresa.
Artiva Biotherapeutics (나스닥: ARTV)는 2025년 11월 12일 동부 표준시 오전 8시에 가상 웹캐스트를 주최하여 AlloNK®와 항-CD20 항체의 자가면역 질환에서의 초기 안전성 및 이식성 데이터를 논의합니다.
공개된 주요 항목: 32명의 환자에서 관찰된 초기 안전성 데이터로, 우수한 내약성 프로파일과 외래 치료의 가능성을 보고; 일관되고 깊은 B-세포 제거를 보여주는 번역적 결과; 10-50배의 더 높은 민감도를 가진 고감도 B-세포 분석; 그리고 난치성 류마티스 관절염에서의 미충족 필요성에 대한 특성화. 생방송 Q&A 및 재생은 회사 웹사이트에서 이용 가능.
Artiva Biotherapeutics (Nasdaq : ARTV) organisera un webinaire virtuel le 12 novembre 2025 à 8 heures, heure de l’Est pour discuter des données initiales de sécurité et de traduction pour AlloNK® plus des anticorps anti-CD20 dans les maladies auto-immunes.
Points clés divulgués : données de sécurité initiales chez 32 patients rapportant un profil de tolérance forable et une faisabilité en ambulatoire ; résultats translationnels montrant une déplétion des B-lymphocytes uniforme et profonde; un test B-cell à haute sensibilité ec une sensibilité 10 à 50 fois supérieure; et la caractérisation du besoin non satisfait dans l’arthrite rhumatoïde réfractaire. Une session de questions-réponses en direct et une rediffusion seront disponibles via le site de l’entreprise.
Artiva Biotherapeutics (Nasdaq: ARTV) wird am 11. November 2025 um 8:00 Uhr ET einen virtuellen Webcast abhalten, um erste Sicherheits- und Translationaldaten für AlloNK® plus Anti-CD20-Antikörper bei Autoimmunerkrankungen zu diskutieren.
Wichtige offengelegte Punkte: erste Sicherheitsdaten bei 32 Patienten, die ein günstiges Verträglichkeitsprofil und Machbarkeit ambulant belegen; translationalle Ergebnisse, die eine einheitliche, tiefe B-Zell-Depletion zeigen; ein hochsensiver B-Zell-Assay mit einer Empfindlichkeit von 10 bis 50-fach höher; und die Charakterisierung des ungedeckten Bedarfs bei refraktärer rheumatoider Arthritis. Ein Live-Q&A und eine Wiederholung sind über die Website des Unternehmens verfügbar.
Artiva Biotherapeutics (ناسداك: ARTV) ستستضيف ويبكاست افتراضي في 12 نوفمبر 2025 الساعة 8 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة بيانات السلامة الأولية والترجمة لـ AlloNK® مع أضداد CD20 في أمراض المناعة الذاتية.
العناصر الرئيسية المعلنة: بيانات السلامة الأولية في 32 مريضاً تشير إلى ملف تحمل مفضل وامكانية خارج العيادة؛ نتائج ترجمة تُظهر استبعاد الخلايا B بشكل موحد وعميق; اختبار ب-خلوي عالي الحساسية بــ 10- إلى 50- ضعف الحساسية؛ وتحديد الاحتياج غير الملبّى في الروماتويد المفلس. سيتوفر تفاعل مباشر وتنزيل للإعادة عبر موقع الشركة.
Positive 32-patient safety dataset showing forable tolerability Uniform, consistent deep B-cell depletion across treated patients High-sensitivity assay with 10–50× greater B-cell detection Feasible outpatient administration and patient management Negative Dataset limited to 32 patients (small sample size) Regimen requires cyclophosphamide/fludarabine conditioning No clinical efficacy or long-term outcome data disclosed
11/03/2025 - 04:05 PM
The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET
Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a forable tolerability profile observed to date and the feasibility of patient management in outpatient rheumatology clinics
Initial translational data highlighting uniform, consistent, deep B-cell depletion supporting AlloNK’s intended mechanism of action
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will host a virtual event discussing initial safety and translational data for AlloNK® in combination with anti-CD20 antibodies across autoimmune diseases.
The webcast will feature:
Initial safety data for 32 patients with autoimmune disease treated with AlloNK + mAb therapy, highlighting a forable tolerability profile observed to date and the ease-of-use of the regimen that includes cyclophosphamide/fludarabine conditioning, and the feasibility of administration and patient management in outpatient rheumatology clinicsInitial translational data highlighting uniform, consistent, deep B-cell depletion across all patients treatedResults from a high-sensitivity B-cell depletion assay with 10- to 50-fold higher sensitivity than typical assays, demonstrating that patients treated with AlloNK + mAb achieve deep B-cell depletion, the intended mechanism of action for AlloNKB-cell reconstitution in patients treated with AlloNK + mAb, demonstrating a consistent preponderance of naïve and transitional cells at reconstitution, in line with what has been observed with auto-CAR-T treatmentCharacterization of the unmet need in refractory rheumatoid arthritis that AlloNK + mAb has the potential to addressInvestors and the general public are invited to listen to the webcast on Wednesday, November 12, 2025, at 8 a.m. ET. A live question and answer session will follow the formal presentation. To register for the event, please click here.
A webcast replay will be made ailable through the "Investors" section on Artivabio.com.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the upcoming webcast to be hosted by Artiva Biotherapeutics, Inc. (the Company); the initial safety and translational data for AlloNK in combination with anti-CD20 monoclonal antibodies (mAb) across autoimmune diseases that will be featured at the webcast; the regimen’s safety, tolerability, ease of use, feasibility of administration and patient management in outpatient rheumatology clinics, and B-cell depletion and reconstitution; the unmet need in refractory rheumatoid arthritis and the potential of AlloNK + mAb to address it; AlloNK’s intended mechanism of action; and the Company’s mission, product candidates, clinical trials, pipeline, and strategic partnerships. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently ailable to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.comMedia: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,
Source: Artiva Biotherapeutics, Inc.
FAQ
When will Artiva (ARTV) present initial AlloNK safety and translational data?
Artiva will host a webcast on November 12, 2025 at 8 a.m. ET with a live Q&A session.
What data did Artiva report for AlloNK + anti-CD20 across autoimmune disease?
The company reported initial safety for 32 patients and translational data showing uniform, deep B-cell depletion.
How sensitive was the B-cell depletion assay reported by Artiva (ARTV)?
Artiva described a high-sensitivity assay with 10- to 50-fold higher sensitivity than typical assays.
What does the AlloNK webcast mean for Artiva shareholders (ARTV)?
The webcast presents initial safety and translational evidence that may inform near-term clinical progress and investor assessment.
How can investors access the Artiva (ARTV) webcast replay?
A replay will be ailable in the Investors section of the company's website after the live event.